Position Statement on Secukinumab in the Management of Plaque Psoriasis: The Malaysian Perspective by Asmah Johar, Suganthi Thevarajah, Agnes Heng, Lee Chin Chan, Chin Chwen Ch’ng, Najeeb Ahmad Mohd Safdar, Pubalan Muniandy, Tarita Taib, Wooi Chiang Tan, Kwee Eng Tey

“…Highlights from the discussion were that (i) the threshold for biologic use should be lower, in line with international guidelines; (ii) studies have shown that secukinumab has several advantages over other biologics which are greater efficacy, sustained efficacy over time, rapid onset of action, and early evidence of possible disease-modifying potential; and (iii) ideal candidates for secukinumab are all patients of moderate to severe psoriasis, including those with history of treatment failure, difficult-to-treat patterns of psoriasis (nail, scalp, and palmoplantar psoriasis), psoriatic arthritis, and comorbidities and those aiming for clear skin. …”
Get full text